RU2016143922A - Терапевтическое средство для применения в лечении опухолей, синдрома приобретенного иммунодефицита и лейкозов путем двойной иммунной биостимуляции - Google Patents
Терапевтическое средство для применения в лечении опухолей, синдрома приобретенного иммунодефицита и лейкозов путем двойной иммунной биостимуляции Download PDFInfo
- Publication number
- RU2016143922A RU2016143922A RU2016143922A RU2016143922A RU2016143922A RU 2016143922 A RU2016143922 A RU 2016143922A RU 2016143922 A RU2016143922 A RU 2016143922A RU 2016143922 A RU2016143922 A RU 2016143922A RU 2016143922 A RU2016143922 A RU 2016143922A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- use according
- mixture
- strain
- paragraphs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (12)
1. Композиция для применения в противоопухолевом химиотерапевтическом лечении, лечении синдрома приобретенного иммунодефицита и лечении лейкоза, содержащая смесь, состоящую из:
- штамма бактерий, принадлежащих виду Lactobacillus reuteri, идентифицированного как Lactobacillus reuteri LRE03, с депозитарным номером DSM 23879, депонированного 05.08.2010 Probiotical SpA в Немецкой коллекции микроорганизмов и клеточных культур (DSMZ GmbH), и/или
- штамма бактерий, принадлежащих виду Lactobacillus salivarius, идентифицированного как Lactobacillus salivarius LS06, с депозитарным номером DSM 26037, депонированного 06.06.2012 Probiotical SpA в Немецкой коллекции микроорганизмов и клеточных культур (DSMZ GmbH).
2. Композиция для применения по п. 1, содержащая смесь с концентрацией бактерий от 1×108 колониеобразующих единиц (КОЕ)/г смеси до 1×1012 КОЕ/г смеси, предпочтительно от 1×109 КОЕ/г смеси до 1×1011 КОЕ/г смеси.
3. Композиция для применения по п. 1 или 2, где указанная смесь содержит или, альтернативно, состоит из:
- штамма бактерий Lactobacillus reuteri LRE03 DSM 23879 и штамма бактерий Lactobacillus salivarius LS06 DSM 26037 в массовом соотношении от 1:5 до 5:1, предпочтительно от 1:3 до 3:1, еще более предпочтительно от 1:2 до 2:1 или 1:1.
4. Композиция для применения по любому из пп. 1-3, дополнительно содержащая гель Aloe или его производное, предпочтительно гель Aloe arborescens; причем еще более предпочтительно гель представляет собой лиофилизированный гель Aloe arborescens.
5. Композиция для применения по любому из пп. 1-4, содержащая лиофилизированный гель Aloe arborescens в количестве от 1 до 25% по массе относительно массы композиции, предпочтительно от 5 до 15% по массе относительно массы композиции.
6. Композиция для применения по любому из пп. 1-5, дополнительно содержащая штамм бактерий, принадлежащих виду Bifidobacterium lactis, идентифицированный как Bifidobacterium lactis Bb 1, с депозитарным номером DSM 17850, депонированный в DSMZ 23.12.2005 BioMan S.r.l. Company, в виде тиндализованного бактериального продукта, где указанный штамм обладает способностью аккумулировать цинк внутри клетки во время его роста в жидкой культуральной среде.
7. Композиция для применения по п. 6, где указанный тиндализованный бактериальный продукт штамма Bifidobacterium animalis ssp. lactis Bb1 DSM 17850 присутствует в количестве от 10 до 50 мг/г композиции, предпочтительно 20 мг/г композиции.
8. Композиция для применения по любому из пп. 1-7, дополнительно содержащая один или более чем один эксципиент, и/или добавку, и/или вспомогательный компонент препаратов, соответствующие критериям пищевой чистоты или фармакологической чистоты, приемлемые для организма, предпочтительно такие как фруктоолигосахариды (FOS), и/или зеленый чай, и/или сукралоза, и/или мальтодекстрины.
9. Композиция для применения по любому из пп. 1-8, предназначенная для применения у человека и животного в качестве противоопухолевого агента.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20140816 | 2014-05-05 | ||
| ITMI2014A000816 | 2014-05-05 | ||
| PCT/IB2015/000602 WO2015170158A1 (en) | 2014-05-05 | 2015-04-30 | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016143922A true RU2016143922A (ru) | 2018-06-05 |
| RU2016143922A3 RU2016143922A3 (ru) | 2018-10-23 |
| RU2721565C2 RU2721565C2 (ru) | 2020-05-20 |
Family
ID=51136602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016143922A RU2721565C2 (ru) | 2014-05-05 | 2015-04-30 | Терапевтическое средство для применения в лечении опухолей, синдрома приобретенного иммунодефицита и лейкозов путем двойной иммунной биостимуляции |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10413576B2 (ru) |
| EP (1) | EP3139940B1 (ru) |
| JP (1) | JP6804984B2 (ru) |
| KR (1) | KR20160148651A (ru) |
| CN (1) | CN107106629B (ru) |
| CA (1) | CA2946463A1 (ru) |
| DK (1) | DK3139940T3 (ru) |
| RU (1) | RU2721565C2 (ru) |
| WO (1) | WO2015170158A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2946463A1 (en) | 2014-05-05 | 2015-11-12 | Giovanni Mogna | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation |
| EP3145518B1 (en) | 2014-05-05 | 2021-02-17 | Probiotical S.p.A. | A composition comprising l. reuteri ler03 and l. salivarius ls06 for use in antiviral and antibacterial treating in a subject undergoing anti-tumor chemotherapy, leukemia treatment or aids therapy |
| US10792314B2 (en) * | 2017-07-05 | 2020-10-06 | Evelo Biosciences, Inc. | Compositions and methods of treating cancer using Bifidobacterium animalis ssp. lactis |
| WO2019075452A1 (en) * | 2017-10-13 | 2019-04-18 | Evelo Biosciences, Inc. | IDENTIFICATION OF BACTERIA FOR CANCER THERAPY |
| CN116916942A (zh) * | 2020-12-17 | 2023-10-20 | 欣巴伦斯有限公司 | 益生菌组合物及其在预防和/或治疗应激相关病症中的用途 |
| CN113215063B (zh) * | 2021-06-16 | 2023-02-21 | 中国药科大学 | 一种唾液乳杆菌及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2213434C (en) * | 1995-12-21 | 2008-12-09 | Abbott Laboratories | Use of lactobacillus reuteri to inhibit cryptosporidiosis in mammals |
| CN1370587A (zh) * | 2002-03-05 | 2002-09-25 | 王舒妍 | 芦荟凝胶的制备方法 |
| JP2006506371A (ja) * | 2002-10-18 | 2006-02-23 | バイオガイア・エイビー | ラクトバチルス・リューテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓｒｅｕｔｅｒｉ）株を用いる哺乳類における免疫機能の改善方法 |
| ITMI20051510A1 (it) * | 2005-08-02 | 2007-02-03 | Proge Farm Srl | Uso di specifici batteri lattici per la preparazione di composizioni iunomodulanti |
| JP2007084533A (ja) | 2005-08-24 | 2007-04-05 | Prima Meat Packers Ltd | 免疫応答調節組成物及び該組成物を有効成分とする食品 |
| ITTO20070555A1 (it) | 2007-07-26 | 2009-01-27 | Bioman S R L | Biomassa arricchita in zinco, procedimento per la sua preparazione e prodotti probiotici, cosmetici, dietetici e nutraceutici comprendenti tale biomassa |
| TWI346554B (en) | 2008-04-30 | 2011-08-11 | Genmont Biotech Inc | Lactobacillus isolates having anti-inflammatory activities and uses of the same |
| KR101001767B1 (ko) | 2008-11-04 | 2010-12-15 | 주식회사한국야쿠르트 | 항 인플루엔자 바이러스 효능을 갖는 락토바실러스 루테리 에이취와이7501 및 이를 유효성분으로 함유하는 제품 |
| WO2010077682A2 (en) * | 2008-12-08 | 2010-07-08 | James Allen Lemke | Treatment of hiv and aids using probiotic lactobacillus reuteri |
| US20110117210A1 (en) * | 2009-11-17 | 2011-05-19 | Andrey Ugolkov | Therapeutic treatment of human cancers using simple salts of zinc |
| US20120107395A1 (en) * | 2010-11-01 | 2012-05-03 | Viva Pharmaceutical Inc. | Probiotic Soft Gel Compositions |
| CN102618452B (zh) | 2011-02-01 | 2014-06-25 | 任发政 | 唾液乳杆菌及其代谢物的制备方法和组合物以及应用 |
| ITMI20110679A1 (it) | 2011-04-20 | 2012-10-21 | Giovanni Mogna | Composizione comprendente batteri probiotici in grado di ripristinare l effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell iperacidita gastrica. |
| ITRM20110477A1 (it) | 2011-09-09 | 2013-03-10 | Giovanni Mogna | Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell |
| KR20130048946A (ko) | 2011-11-03 | 2013-05-13 | 가톨릭대학교 산학협력단 | 락토바실러스 루테리 ｃｓ132 또는 이의 배양물을 포함하는 항암용 조성물 |
| ITMI20120131A1 (it) | 2012-02-01 | 2013-08-02 | Probiotical Spa | Batteri probiotici microincapsulati multistrato, loro produzione ed uso |
| CA2946463A1 (en) | 2014-05-05 | 2015-11-12 | Giovanni Mogna | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation |
| EP3145518B1 (en) | 2014-05-05 | 2021-02-17 | Probiotical S.p.A. | A composition comprising l. reuteri ler03 and l. salivarius ls06 for use in antiviral and antibacterial treating in a subject undergoing anti-tumor chemotherapy, leukemia treatment or aids therapy |
-
2015
- 2015-04-30 CA CA2946463A patent/CA2946463A1/en not_active Abandoned
- 2015-04-30 RU RU2016143922A patent/RU2721565C2/ru active
- 2015-04-30 US US15/307,756 patent/US10413576B2/en active Active
- 2015-04-30 DK DK15736584.2T patent/DK3139940T3/da active
- 2015-04-30 WO PCT/IB2015/000602 patent/WO2015170158A1/en active Application Filing
- 2015-04-30 EP EP15736584.2A patent/EP3139940B1/en active Active
- 2015-04-30 KR KR1020167033185A patent/KR20160148651A/ko not_active Application Discontinuation
- 2015-04-30 JP JP2016566657A patent/JP6804984B2/ja active Active
- 2015-04-30 CN CN201580023472.1A patent/CN107106629B/zh not_active Expired - Fee Related
-
2019
- 2019-07-30 US US16/526,715 patent/US20190350989A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015170158A1 (en) | 2015-11-12 |
| EP3139940A1 (en) | 2017-03-15 |
| JP6804984B2 (ja) | 2020-12-23 |
| KR20160148651A (ko) | 2016-12-26 |
| JP2017514857A (ja) | 2017-06-08 |
| DK3139940T3 (da) | 2021-05-17 |
| RU2016143922A3 (ru) | 2018-10-23 |
| CN107106629A (zh) | 2017-08-29 |
| WO2015170158A8 (en) | 2016-12-01 |
| CA2946463A1 (en) | 2015-11-12 |
| US10413576B2 (en) | 2019-09-17 |
| US20190350989A1 (en) | 2019-11-21 |
| RU2721565C2 (ru) | 2020-05-20 |
| US20170042951A1 (en) | 2017-02-16 |
| EP3139940B1 (en) | 2021-02-17 |
| CN107106629B (zh) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016143922A (ru) | Терапевтическое средство для применения в лечении опухолей, синдрома приобретенного иммунодефицита и лейкозов путем двойной иммунной биостимуляции | |
| RU2010147343A (ru) | ИЗОЛИРОВАННЫЙ ШТАММ МИКРООРГАНИЗМА Lactobacillus plantarum Inducia DSM 21379 В КАЧЕСТВЕ ПРОБИОТИКА, УСИЛИВАЮЩЕГО ВРОЖДЕННЫЙ ИММУНИТЕТ ОРГАНИЗМА, ПРОДУКТ И КОМПОЗИЦИЯ, СОДЕРЖАЩИЕ УПОМОМЯНУТЫЙ МИКРООРГАНИЗМ, И ПРИМЕНЕНИЕ УПОМЯНУТОГО МИКРООРГАНИЗМА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА, КОТОРОЕ УСИЛИВАЕТ КЛЕТОЧНЫЙ ИММУНИТЕТ | |
| SI3209310T1 (en) | Compositions containing bacterial strains | |
| JP2015213501A5 (ru) | ||
| EP3145518B1 (en) | A composition comprising l. reuteri ler03 and l. salivarius ls06 for use in antiviral and antibacterial treating in a subject undergoing anti-tumor chemotherapy, leukemia treatment or aids therapy | |
| JP2019508486A5 (ru) | ||
| RU2016129178A (ru) | Lactobacillus salivarius для лечения мастита | |
| MY193248A (en) | Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation | |
| EP3452073A1 (en) | The use of phycocyanins, purified or as present in cyanobacterial microalgae or extracts thereof, as prebiotics, to enhance the viability, gastrointestinal survival, pathogen-fighting ability, and the overall health-enhancing properties of probiotic cultures and products. | |
| Tanriover et al. | Use of probiotics in various diseases: Evidence and promises | |
| US20200197453A1 (en) | Composition for use as a support therapy for treatment of tumours, aids and leukaemia | |
| Tsai et al. | The relative efficacy of different strain combinations of lactic acid bacteria in the reduction of populations of Salmonella enterica Typhimurium in the livers and spleens of mice | |
| Lim | Anti-Helicobacter pylori activity of antimicrobial substances produced by lactic acid bacteria isolated from Baikkimchi | |
| Xu et al. | Lactobacillus casei JY300-8 generated by 12C6+ beams mutagenesis inhibits tumor progression by modulating the gut microbiota in mice | |
| Salleh et al. | Antimicrobial activity of cell free supernatant of lactic acid bacteria isolated from fermented Durian flesh against multiple antibiotic resistance’s Salmonella associated with food poisoning cases in Malaysia | |
| Njoki et al. | Probiotic potential of lactic acid bacteria isolated from coconut (Cocos Nucifera) wine (mnazi) in Kenya | |
| Ghaderian et al. | Probiotic therapy, what is the most effective method for host protection against enteric pathogen | |
| WO2018078599A4 (en) | Composition for the preventive or curative treatment of liver disorders | |
| Bello et al. | Antibacterial activity of lactic acid bacteria isolated from fresh pepper and tomatoes against common food pathogens | |
| Sharma et al. | A REVIEW EXAMINING PROBIOTIC POTENTIAL OF PUTTING VARIOUS POSITIVE EFFECTS UPON THE HEALTH OF HUMAN BEINGS | |
| Behare et al. | Evaluation of bile tolerance in dairy and human origin Lactobacillus fermentum strains | |
| Lim et al. | Selection of Lactobacillus Species Inhibiting Enteropathogenic Bacteria and Potential Use as Probiotics |